Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Novel Biomarkers in Cardiovascular Disease: A Review

The Indonesian Biomedical Journal · Vol. 2 No. 3 (2010) · hlm. 66–66

DOI
10.18585/inabj.v2i3.122
ISSN
2085-3297, 2355-9179
Terbit
2010-12-01
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. New markers or tests are often presented too early to the medical profession, potentially leading to overuse and, thus, extra burden and costs to patients, the healthcare industry, and the economy. The challenge for clinicians and medical researchers is how to optimally apply existing and new markers/tests.CONTENT: Biomarkers are biological parameters that can be objectively measured and quantified as indicators of normal biologic processes, pathogenic processes, or responses to a therapeutic intervention. Typically thought of as disease process screening, diagnosing, or monitoring tools, biomarkers may also be used to determine disease susceptibility and eligibility for specific therapies. Cardiac biomarkers are protein components of cell structures that are released into circulation when myocardial injury occurs. They play a pivotal role in the diagnosis, risk stratification, and treatment of patients with chest pain and suspected acute coronary syndrome (ACS) as well as those with acute exacerbations of heart failure.SUMMARY: Active investigation has brought forward an increasingly large number of novel candidate markers but few have withstood the test of time and become integrated into contemporary clinical care because of their readily apparent diagnostic, prognostic, and/or therapeutic utility. With regard to the more novel biomarkers, careful thought is needed with regard to the appropriate target populations for discovery and validation, as well as the criteria used to sort out the contenders from the pretenders.KEYWORDS: biomarker, cardiovascular disease, atherosclerosis, acute myocardial infarction, heart failure, risk stratification, diagnosis, prognosis

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 143 tautan kepenulisan bersama · 70 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Udayana University
  • University of Indonesia
  • Universitas Trisakti
  • Universitas Airlangga
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Nurrani Mustika DewiPadjadjaran University90
Suryani As’ádHasanuddin University15
Gatot Susilo LawrenceHasanuddin University7
Yani LinaHasanuddin University6
Ilhamjaya PatellongiHasanuddin University6
Cynthia Retna SartikaPT Prodia StemCell Indonesia (Indonesia)5
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Melisa Intan BarlianaPadjadjaran University4
Keri LestariPadjadjaran University4
Irma Ruslina DefiPadjadjaran University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Rima HaifaPT Prodia StemCell Indonesia (Indonesia)3
Trilis YuliantiHasanuddin University3
Irma Rahayu LatarissaPadjadjaran University3
Ida Paulina SorminHasanuddin University3
Erizal SugionoHasanuddin University3
Keri Lestari DandanPadjadjaran University3
Lucia HerminawatiHasanuddin University3
Yenny SurjawanHasanuddin University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ferry SandraUniversitas Trisakti2
Ahmad FariedPadjadjaran University2
Marsetio DonosepoetroUniversitas Airlangga2
Burhanuddin BaharHasanuddin University2
Widjaja LukitoSEAMEO Regional Center for Food and Nutrition2
Indriyanti Rafi SukmawatiHasanuddin University2
Antonia Anna LukitoHasanuddin University2
Mansyur ArifHasanuddin University2
Aziiz Mardanarian RosdiantoPadjadjaran University2
Adziqa Ammara QiantoriPadjadjaran University2
Candra NinghayuHasanuddin University1
Anna MeilanaPadjadjaran University1
Cissy Bana KartasasmitaPadjadjaran University1
Irmansyah IrmansyahNational Research and Innovation Agency1
Terawan Agus PutrantoGatot Soebroto Army Hospital1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Novel Biomarkers in Cardiovascular Disease: A Review</dc:title><dc:creator>Anna Meiliana</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:subject>cardiovascular biomarkers</dc:subject><dc:subject>cardiac biomarkers</dc:subject><dc:subject>acute coronary syndrome</dc:subject><dc:subject>acute myocardial infarction</dc:subject><dc:subject>heart failure</dc:subject><dc:subject>atherosclerosis</dc:subject><dc:subject>risk stratification</dc:subject><dc:subject>prognosis</dc:subject><dc:subject>biomarker validation</dc:subject><dc:description xml:lang="en">BACKGROUND: The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. New markers or tests are often presented too early to the medical profession, potentially leading to overuse and, thus, extra burden and costs to patients, the healthcare industry, and the economy. The challenge for clinicians and medical researchers is how to optimally apply existing and new markers/tests.CONTENT: Biomarkers are biological parameters that can be objectively measured and quantified as indicators of normal biologic processes, pathogenic processes, or responses to a therapeutic intervention. Typically thought of as disease process screening, diagnosing, or monitoring tools, biomarkers may also be used to determine disease susceptibility and eligibility for specific therapies. Cardiac biomarkers are protein components of cell structures that are released into circulation when myocardial injury occurs. They play a pivotal role in the diagnosis, risk stratification, and treatment of patients with chest pain and suspected acute coronary syndrome (ACS) as well as those with acute exacerbations of heart failure.SUMMARY: Active investigation has brought forward an increasingly large number of novel candidate markers but few have withstood the test of time and become integrated into contemporary clinical care because of their readily apparent diagnostic, prognostic, and/or therapeutic utility. With regard to the more novel biomarkers, careful thought is needed with regard to the appropriate target populations for discovery and validation, as well as the criteria used to sort out the contenders from the pretenders.KEYWORDS: biomarker, cardiovascular disease, atherosclerosis, acute myocardial infarction, heart failure, risk stratification, diagnosis, prognosis</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2010-12-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v2i3.122</dc:identifier><dc:identifier>10.18585/inabj.v2i3.122</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 2 No 3 (2010); 66-66</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/122/149</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>